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Background: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS).
Methods: This multicenter retrospective observational study included 135 patients. Histological subtype,
characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded.
Results: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and
undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of
cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the
median time to first SRE was 4 months (range 1–9). The most common SRE was the need for radiotherapy (28%)
followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1–14). SREs
were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates
significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an
improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105).
Conclusions: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates
in this setting.
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Soft tissue sarcomas (STS) are a group of rare and hetero-
geneous cancers, accounting for less than 1% of all human
tumors. Their biological behavior is characterized by local
aggressiveness and tendency to hematogenous spreading.
Almost 50% of STS patients develop metastatic disease
[1], mainly within three years from initial diagnosis. The
distribution of metastases from STS varies, depending on
the primary site and histological subtype. For example,
those arising from the extremities mainly spread to the* Correspondence: a.frezza@unicampus.it
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reproduction in any medium, provided the orlungs, and those arising from the abdominal cavity, usu-
ally metastasizing to liver and peritoneum.
Even if no extensive data are currently available on the
skeletal involvement in STS patients, the daily clinical prac-
tice suggests that the development of bone metastases and
the subsequent occurrence of skeletal related events (SREs)
(namely pathological fracture, hypercalcaemia, spinal cord
compression, need for surgery or palliative radiotherapy
for refractory pain) [2] can be part of the natural history
of this disease, can significantly modified a patient’s per-
formance status and deeply affect quality of life. Further-
more, the role of bisphosphonates therapy, known to be
effective in preventing or delaying SREs and in relieving
from bone pain in different human tumors [3,4], has never
been assessed in STS patients.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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study was to better define the natural history of skeletal
metastases from STS, to investigate their possible prog-
nostic value and to explore different treatment options
which might guide future practice.
Patients and methods
Patient population
Almost 1250 patients affected by metastatic soft tissue
sarcoma have been screened. Among these, 135 patients
with radiologically (plain films, CT scan, MRI scan) proven
bone metastases from STS have been selected and retro-
spectively included in the present analysis. All patients
were diagnosed and treated between 1999 and 2011 at
University College Hospital (London Sarcoma Service),
University Campus Bio-Medico (Rome), Ospedale Santa
Chiara (Pisa), Policlinico P. Giaccone (Palemo), Istituto
Oncologico Veneto (Padova), Universita’ Politecnica delle
Marche (Ancona), and Ospedale Giovanni XXIII (Bari).
Data collection
The following clinical data have been retrospectively col-
lected: age, gender, primary histological subtype (classified
according to 2002 World Health Organization classifica-
tion of the tumors [5]), grade (according to the French
federation of Cancer Centre Sarcoma Group [6]), primary
site, presence of bone metastases at the time of diagnosis,
number (equal or less than 5, more than 5) and site of
bone metastases, treatments received for bone lesions
(chemotherapy, zoledronic acid, palliative radiotherapy or
surgery), presence of SREs, time to first SREs and survival
from the time of skeletal disease diagnosis. The clinical
data were both manually and electronically extracted. The
completeness of the series of each centre was based on
the contribution of each author. The study has been
conducted in compliance with the Helsinki Declaration
and has been approved by the ethic committee at Univer-
sity Campus Bio-Medico.
Statistical analysis
In the univariate model all the clinical variables were
evaluated as predictors for shorter time to bone metasta-
sis, higher risk of skeletal morbidity (SREs), and shorter
time from SREs to death. Patients who did not have a
recorded date for a specific event were censored after
the date of last follow-up. All survival intervals were de-
termined by the Kaplan-Meier product-limit method [7]
while differences in survival according to clinical pa-
rameters or treatment were evaluated by the log-rank
test [8] and described by the Kaplan-Meier method. The
last follow-up for patients included in the analysis was
November 2011 and the event was death. SPSS software




Among the enrolled 135 patients 53% were male (71/135).
The median age was 52 years (range 23 to 86). All patients
were affected by a histologically proven sarcoma of the
soft tissue and all the diagnoses were centrally reviewed by
a pathologist with expertise in this field. Leiomyosarcoma
was diagnosed in 27% (36/135) of the patients while
14% (19/135) were affected by undifferentiated pleo-
morphic sarcoma, 13% (17/135) by angiosarcoma, 7%
(10/135) by liposarcoma, 7% (9/135) by malignant epithe-
lioid hemangioendothelioma, 6% (8/135) by malignant
peripheral nerve sheet tumor (MPNST), 5% (7/135) by
synovial sarcoma and 21% (29/135) by other different
histological subtypes. The histological grade was G1 in 4%
(6/135) of patients, G2 (28/135) in 21% of patients, and
G3 in 75% (101/135). The primary site of the disease was
limbs or limb girdles in 50% (67/135) of patients, body
cavity in 33% (45/135) and trunk in 17% (23/135). Patient
characteristics are summarized in Table 1.
Natural history of bone metastases from soft
tissue sarcoma
In 27% (36/135) of cases, bone metastases were present at
the time of diagnosis. Less than 5 bone metastases were
detected in 60% (81/135) of patients while more than 5
were present in the remaining 40% (54/135). Among the
analyzed patients, the spine was involved in 51% (69/135)
of cases, being the most common skeletal site; hip/pelvis
was involved in 20% (27/135) of patients, long bones in
15% (20/135) and other sites 14% (19/135). A SRE devel-
oped in 40% (54/135) of patients and median time to first
SRE was 4 months (range: 1–9). The most common SRE
was the need for radiotherapy occurring in 28% (38/135)
of patients followed by pathologic fracture (22%, 30/135),
need for surgery (21%, 29/135), cord compression (13%,
18/135) and hypercalcaemia occurring only in 3% (4/135)
of patients. These results are summarized in Table 2.
Prognostic value of bone metastases and treatment
options
Patients survived for a median of 6 months after diagnosis
of bone metastases (range: 1–14). The number of bone
metastases did not significantly correlate with survival in
STS patients (P = 0.63), while both the occurrence of SREs
and an early time to first SRE were associated with a de-
creased overall survival (OS) (P = 0.04 and P = 0.002).
Among the enrolled patients, 72% (97/135) received
chemotherapy. The median number of treatment lines
was 2 (range: 0–4) and the most wildly used drugs in-
cluded doxorubicin, ifosfamide, gemcitabine, docetaxel
Table 1 Patient characteristics
Characteristic N patients (%)
Median age (years) 52 (range: 23–86)
Gender
• Male 71 (53)
• Female 64 (47)
Histology
• Leiomyosarcoma 36 (27)
• Undifferentiated pleomorphic sarcoma 19 (14)
• Angiosarcoma 17 (13)
• Liposarcoma 10 (7)
• Malignant epithelioid hemangioendothelioma 9 (7)
• MPNST 8 (6)
• Synovial sarcoma 7 (5)
• Others 29 (21)
Tumour grade
• G1 6 (4)
• G2 21 (28)
• G3 101 (75)
Primary site
• Limbs or limb girdles 67 (50)
• Body cavity 45 (33)
• Trunk 23 (17)




• Time of diagosis 36 (27)
• After diagnosis 99 (73)
Number of bone metastases
• ≤ 5 81 (60)
• > 5 54 (40)
Bone metastases site
• Spine 69 (51)
• Hip/pelvis 27 (20)
• Long bones 20 (15)
• Others 19 (14)
SRE development
• Yes 54 (40)
• No 81 (60)
• Median time to first SRE (months) 4 (range: 1–9)
SRE type
• Palliative radiotherapy 28 (38)
• Pathological fracture 30 (22)
• Cord compression 18 (13)
• Hypercalcaemia 4 (3)
• Palliative surgery 29 (21)
Table 3 Treatment options for bone metastases from soft
tissue sarcoma
Treatment N patients (%)
• Biphosphonates 81 (60)
• Radiotherapy 42 (31)
• Surgery 29 (21)
• Other 3 (2)
• No specific treatment 52 (39)
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bisphosphonates at the time of bone metastasis diagnosis.
Radiotherapy was given to 31% (42/135) of the patients,
21% (29/135) were treated with surgery and 2% (3/135)
with other local approaches. On the contrary, 39% (52/
135) did not receive any specific treatment. These results
were summarized in Table 3. A subgroup analysis re-
vealed that bisphosphonates significantly prolonged me-
dian time to first SRE (5 versus 2 months; P = 0.002).
Conversely, bisphosphonate therapy did not determine an
improvement in terms of OS, even if a favorable trend
was identified for treated patients (median, 7 versus 5
months, respectively; P = 0.105). These results are sum-
marized in Table 4.
Discussion
The skeleton is the third most frequent site of metasta-
ses from solid tumors and the vast majority of bone me-
tastases affect patients with primary breast, lung or
prostate cancer. However, the development of metastatic
bone disease and the occurrence of SREs can complicate
several different malignancies, causing a worsening of
patient’s quality of life and requiring a complex manage-
ment which significantly impact on health resources [9].
Among patients affected by STSs, bone metastases
occur in almost 10%, with a great variability depending onthe histological subtypes. From previous smaller reports
[10,11], angiosarcoma, dedifferentiated liposarcoma and
alveolar soft part sarcoma showed the higher incidence of
skeletal metastases with a percentage of bone involvement
of almost 50%. The axial skeleton is the most common
site of localization while the involvement of long bones is
rarer and usually limited to diaphyses. Radiologically,
bone metastases from STS are described as lytic in more
than 80% of cases [12] and the detection of a pathological
fracture by radiography is not an uncommon finding.
Although our dataset confirmed the variability in bone
metastases incidence among different subtypes of sarcoma,
leiomyosarcoma, undifferentiated pleomorphic sarcoma
and angiosarcoma were the most common histotypes
associated with bone involvement. As expected, high
Table 4 Impact of bisphosphonate therapy on overall
survival and time to first skeletal related events




Median time to first
SRE (months)
5 2 0.002
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or limb girdles were both found to be risk factors for the
development of bone metastases. Concordantly with pre-
vious findings, the axial skeleton was involved in 70% of
the enrolled patients while long bones only in 15%. More-
over, for the first time in the present study, the rate of
SREs was assessed and they have been found to occur
in 40% of the included patients. The most common
SREs were represented by the need for radiotherapy,
mainly in the context of pain management, and patho-
logical fractures. Interestingly, as already known for breast
[13] and prostate [14] cancer patients, the occurrence of
SREs, especially within six months from the diagnosis of
bone metastases, strongly correlates with a decreased OS
(P = 0.002).
Despite these results, which clearly describe the extent
of this problem and its relevance in terms of prognosis
and quality of life, there are currently no clear guidelines
regarding the management of bone metastases from
STS. This issue is confirmed by the extreme heterogen-
eity of treatment approaches observed in this population.
Radiotherapy was used in almost one third of the pa-
tients in our dataset, mainly to improve pain control or
to reduce the risk of a pathological fracture, while the
use of surgery was limited to 21% of the cases.
It is interesting to underline that 60% of the patients were
started on bisphosphonates at the time of bone metastasis
diagnosis, including pamidronate or zoledronic acid. The
selection criteria for administration of bisphosphonates
are not clear but are mainly dependent on institutional
practice. The results from the present analysis show how
the use of bisphosphonates in patients with bone metasta-
ses from STS significantly delays the first SRE (P = 0.002)
and seems to be associated with a favorable trend in terms
of survival, although the statistical significance was not
reached (P = 0.105) in this cohort.Conclusions
On the basis of the present study, the need for a
standardization of bone metastases treatment in STS
patients is recommended in order to improve quality
of life and perhaps impact on survival.
Although the value of our results is limited by the retro-
spective nature of the study we believe that, given thedelay demonstrated in the time to the first SRE, the use of
bisphosphonates in this setting should be considered.
Further studies are warranted which aim to corrobor-
ate these results and to properly explore the impact of
bisphosphonates therapy on survival of STS patients.
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